Business Wire

Samsung Expands Galaxy AI as Consumer Desire for Mobile AI Grows

14.7.2025 10:37:00 CEST | Business Wire | Press Release

Share

Samsung has today announced a major commitment to expand Galaxy AI to over 400 million devices globally by the end of 2025. This builds on its 2024 milestone of bringing Galaxy AI to more than 200 million devices, beginning with the Galaxy S24 series.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711123209/en/

Galaxy AI adoption accelerates, with 70% of Galaxy S25 users engaging AI-powered features like Circle to Search, Photo Assist, and Note Assist

Since launch, Galaxy AI has helped define a new era of mobile AI innovation – transforming what’s possible on smartphones. Today, over 70% of Galaxy S25 users actively engage with a growing suite of AI-powered features developed in collaboration with Samsung and Google.

Among these, Google Gemini has seen the most notable growth, with usage tripling across the latest Galaxy S series. Through close collaboration with Samsung, Gemini is deeply integrated across Galaxy devices – connecting with first-party apps to deliver helpful and personalised responses.

Mindy Brooks, Vice President, Android Consumer Product & Experience, Google, said: "Through close collaboration with Samsung, Gemini works seamlessly across its devices and connects with its first-party apps to provide helpful and personalised responses. For example, Gemini’s live video capabilities have been optimized for the Flip's front screen camera, and Gemini on Galaxy Watch leverages context from your phone."

Consumers Are Turning to Mobile AI for Everyday Tasks

One year on from the inaugural Galaxy AI Forum, Samsung is sharing new insights into how AI is transforming daily life. Research conducted with Symmetry Research reveals growing reliance on mobile AI and evolving expectations for more personalised, proactive features:

  • 47% of consumers say their daily routines would be disrupted without AI tools such as personalised notifications, AI-powered search, and voice assistance.
  • 45% now use voice commands as often as they type – highlighting a shift in how users interact with their devices.

These trends point to growing demand for multimodal, intelligent, and intuitive AI experiences.

Democratising Mobile AI for All

Samsung’s expansion of Galaxy AI to 400 million devices reflects its commitment to democratising the power and possibilities of mobile AI. Whether through intuitive voice features, on-device privacy, or cross-device intelligence, Samsung is building a future where AI is seamlessly embedded in the smartphone – the device that’s always in your hand.

Jisun Park, Corporate Executive Vice President & Head of Language AI Team, Mobile eXperience Business at Samsung Electronics, concluded: “Some see AI as the start of a ‘post smartphone’ era, but we see it differently. We’re building a future where your devices don’t just respond, they become smarter to anticipate, see, and work quietly in the background to make life feel a little more effortless.”

Learn more about how Samsung and its industry partners are shaping the future of mobile AI here: https://www.samsungmobilepress.com/feature-stories/samsung-continues-to-expand-galaxy-ai-as-consumers-show-increasing-reliance-on-mobile-ai

View source version on businesswire.com: https://www.businesswire.com/news/home/20250711123209/en/

Contacts

George Leney
g.leney@samsung.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye